SENTENCE,R1,R2,R3,LABEL
"""Response rates were 22% for CAPIRI + C, 48% for CAPIRI + P, 32% for FOLFIRI + C and 46% for FOLFIRI + P""",-1.0,-1.0,-1.0,-1
"""Patients with lung metastases, an erythrocyte sedimentation rate < or =70 mm h(-1) and neutrophil counts < or =6000 microl(-1) (group I) were randomised to arm A: sc-IL-2, sc-IFN-alpha2a, peroral 13-cis-retinoic acid (po-13cRA) (n=78), or arm B: arm A plus inhaled-IL-2 (n=65)""",-1.0,-1.0,-1.0,-1
We constructed Ces2 cluster knockout mice lacking all eight Ces2 genes (Ces2-/- strain) as well as humanized hepatic or intestinal CES2 transgenic strains in this Ces2-/- background,-1.0,-1.0,-1.0,-1
"""However, relevant stoma morbidity after rectal cancer surgery exists and has a significant impact on quality of life""",-1.0,0.0,0.0,0
"""BACKGROUND: Eribulin's clinical benefit remains unclear so, studies analyzing its effectiveness in routine clinical practice are interesting""",-1.0,-1.0,-1.0,-1
"""Drug-related toxicity, particularly hand-foot syndrome, mucositis and diarrhoea, was more frequent with capecitabine-docetaxel and there was a higher incidence of drug-related treatment withdrawals with this combination""",-1.0,-1.0,-1.0,-1
"""The organ preservation rate, tumour regression grade, local recurrence rate, disease-free survival, overall survival, adverse effects, and quality of life will also be analysed""",1.0,0.0,1.0,1
BACKGROUND/AIM: Capecitabine plus oxaliplatin (CapeOX) therapy is used as an adjuvant chemotherapy regimen for patients with colorectal cancer (CRC),-1.0,-1.0,-1.0,-1
Patients with durable response showed significantly greater incidence of estrogen receptor (ER) positivity (81.8% vs,-1.0,0.0,0.0,0
Pretreatment DPD screening was mandated by EMA guidelines in April 2020 and widely adopted thereafter,-1.0,0.0,0.0,0
"""BACKGROUND: Bevacizumab is commonly used in combination with chemotherapy in the treatment of metastatic colorectal cancer, but to date, despite extensive research, no predictive or prognostic biomarkers for bevacizumab have been identified""",-1.0,-1.0,-1.0,-1
"""In a subgroup analysis, the addition of varlitinib appeared to provide a PFS benefit in female patients (median, 4.1Â versus 2.8 months HR, 0.59 95% CI, 0.28-1.23) and those with gallbladder cancer (median, 2.9 versus 1.6 months HR, 0.55 95% CI, 0.26-1.19)"" ",-1.0,-1.0,-1.0,-1
"""Treatment required modification for 22 patients due to adverse events, most frequently hand-foot syndrome (18 patients)""",1.0,1.0,1.0,1
"""A multivariate logistic regression analysis, adjusted for age, comorbidity and CAPE-regimen, confirmed the role of 5-fluorouracil degradation rate as a predictor of G3-4 toxicity occurrence (ORâ€‰=â€‰10.9 [95% IC 1.2-96.2], Pâ€‰=â€‰0.03)""",1.0,1.0,1.0,1
"""DESIGN, SETTING, AND PARTICIPANTS: A single-arm phase 2 clinical trial was conducted at a large academic hospital from August 22, 2013, to May 22, 2018, among 49 patients with previously untreated locally advanced unresectable pancreatic cancer as determined by multidisciplinary review""",0.0,0.0,0.0,0
There are several studies describing a hereditary (pharmacogenetic) disorder in which individuals with absent or significantly reduced DPD activity may even develop a life-threatening toxicity following exposure to 5-FU,1.0,1.0,0.0,1
"""Capecitabine has been reported to increase serum phenytoin levels and the international normalized ratio in patients receiving concomitant phenytoin and warfarin, respectively""",0.0,1.0,1.0,1
"""The mean Wexner scale score was 9.2, and a high score correlated with symptoms of diarrhea and defecation problems at T4""",1.0,0.0,1.0,1
"""This suggests caution should be used when irinotecan is combined with substrates of CES, and warrants further study""",0.0,-1.0,1.0,1
"""The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1-p3, with PD1, PD2, and survival was studied by Cox regression models""",-1.0,0.0,0.0,0
"""The maximum dose intensity of the continuous fixed-dose schedule is 8750 mg/m2/week compared with 11,666 mg/m2/week for the standard dose and schedule (2500 mg/m2/day for 14 days every 21 days)""",0.0,0.0,0.0,0
PATIENTS AND METHODS: MBC patients (â‰¥65 years) were randomized between pegylated liposomal doxorubicine or capecitabine,0.0,0.0,0.0,0
SNPs in genes classified as potentially damaging (Sorting Intolerant from Tolerant and Polymorphism Phenotyping v2) were tested for association with toxicity in a validation cohort of 319 capecitabine-treated patients,1.0,1.0,1.0,1
"""AIM: The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorinÂ and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)""",0.0,-1.0,-1.0,-1
"""Eligible patients with advanced gastric cancer were treated with capecitabine at a fixed dose 1,000 mg daily (days 1-28 continuously, every 5 weeks) until disease progression or significant toxicity""",1.0,0.0,1.0,1
"""The MTD was docetaxel, 40 mg/m2 days 1 and 8 carboplatin, AUC = 2 days 1 and 8 and capecitabine, 1500 to 2000 mg/m2 days 1 to 10 in a 21-day cycle""",0.0,-1.0,0.0,1
CONCLUSION: A patient receiving capecitabine-containing chemotherapy developed persistent but reversible cerebellar ataxia.,1.0,1.0,1.0,1
"""All regimens were generally well tolerated, although 1 patient in SOX was associated with grade 3 enterocolitis, which was considered a dose-limiting toxicity""",1.0,-1.0,1.0,-1
" although 1 patient was associated with grade 3 enterocolitis, which was considered a dose-limiting toxicity""",,,,1
"""In conclusion, bevacizumab administered in combination with paclitaxel, or in combination with capecitabine if other chemotherapy regimens are not appropriate, may be considered as an option for the first-line treatment of patients with HER2-negative metastatic breast cancer.""",-1.0,-1.0,-1.0,-1
CONCLUSIONS: UGT1A1 genotype-directed dosing (gCAPIRINOX) appears to be feasible with favorable rates of hematologic toxicity compared with prior 3-drug studies in unselected patients,-1.0,-1.0,-1.0,-1
"""Patients received a median of 12 cycles of T-DM1 (range 1-34), and six remain on treatment at the time of analysis""",-1.0,-1.0,0.0,-1
" and six remain on treatment at the time of analysis""",,,,0
Two phase II studies of irinotecan plus oxaliplatin in second-line patients report median survivals of 11-12 months,-1.0,-1.0,-1.0,-1
"""Capecitabine was administered concurrently at 825 mg/m2 bid on days 1 to 14 and 22 to 35, with oxaliplatin starting at 50 mg/m2 on days 1, 8, 22, and 29 with planned escalation steps of 10 mg/m2""",-1.0,-1.0,-1.0,-1
Preclinical and clinical evidence indicating that dose intensification of the oral fluorouracil prodrug might result in improved therapeutic results led us to the present randomized multicenter phase II study,0.0,-1.0,0.0,0
"""As NCI/NIH common toxicity criteria, grade 3/4 anemia, neutropenia and thrombocytopenia occurred in two, one and one patients, respectively""",1.0,1.0,1.0,1
Clinicians and clinical pharmacists should educate and counsel the patients regarding the likely adverse effects of their chemo drugs because the early identification of toxic symptoms is crucial to reduce further complications to the patient.,1.0,0.0,1.0,1
"""The 3-year OS rates of the DOX group, the XELOX group and the surgery group were 56.9, 44.6, and 34.7%, respectively""",-1.0,-1.0,-1.0,-1
CONCLUSIONS: Combining sorafenib and standard chemoradiotherapy with capecitabine is highly active in patients with KRAS-mutated LARC with acceptable toxicity and deserves further investigation,-1.0,-1.0,-1.0,-1
Lapatinib-associated DEs appear to differ clinically from those associated with EGFR TKIs in both frequency and severity.,-1.0,-1.0,-1.0,-1
"""We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study""",-1.0,-1.0,-1.0,-1
"""PATIENTS AND METHODS: One thousand and five hundred patients with early breast cancer were entered to the Finland Capecitabine trial (FinXX) between January 2004 and May 2007, and were randomly assigned to receive either three cycles of adjuvant TX (docetaxel, capecitabine) followed by three cycles of CEX (cyclophosphamide, epirubicin, capecitabine",-1.0,-1.0,-1.0,-1
"""The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs 14.3Â months (HR 0.80",-1.0,-1.0,-1.0,-1
"""In both cases, the patients were switched from oral capecitabine to a continuous intravenous 5-fluorouracil infusion and were able to continue treatment without a relapse of hepatotoxicity.""",1.0,1.0,1.0,1
"""Trastuzumab, cisplatin and capecitabine were also given for six cycles, then trastuzumab q3w until disease progression or unmanageable toxicity""",1.0,-1.0,-1.0,-1
capecitabine was also given until disease progression or unmanageable toxicity,,,,1
CONCLUSIONS: Self-reported compliance with capecitabine-based therapy in clinical practice is high and seems to be adversely affected by side effects.,1.0,0.0,1.0,1
"""The primary analysis result did not show a difference in OS for the bevacizumab arm compared to the placebo arm [hazard ratio, 1.11 (95% CI, 0.79-1.56)",-1.0,-1.0,-1.0,-1
"""Two million people worldwide start fluoropyrimidine chemotherapy each year, with 20-30% developing severe or life-threatening adverse effects, often attributable to a genetic predisposition such as dihydropyrimidine dehydrogenase deficiency""",1.0,1.0,1.0,1
"""SNPs and clinical baseline factors that were univariably associated with HFS with PÂ â‰¤Â 0.10, were tested in a multivariable model using logistic regression""",-1.0,0.0,0.0,1
"""Genotypes in DNA repair genes XRCC1 (G28152A), XRCC3 (A4541G), XRCC3 (C18067T), RAD51 (G315C), and GSTP1 (A313G) were determined by pyrosequencing technology""",-1.0,-1.0,-1.0,-1
Its toxicity and activity is similar to that observed when intravenous 5-fluorouracil or capecitabine are given alone,1.0,1.0,1.0,1
We strongly suggest a stepwise approach using phenotype testing upfront because of the higher sensitivity and the lower cost to society.,-1.0,0.0,-1.0,0
Toxicity was assessed by continuous evaluations of treatment-emergent adverse events (AEs) and changes from baseline in laboratory values,1.0,1.0,1.0,1
Capecitabine is also effective as monotherapy in pretreated patients and phase II data for capecitabine as first-line monotherapy are also promising,1.0,0.0,0.0,0
"""OBJECTIVES: FOLFIRINOX, gemcitabine/nab-paclitaxel (gem-nab/P), and gemcitabine-capecitabine (gem-cap) demonstrated superiority over gemcitabine monotherapy for pancreatic cancer (PC)""",-1.0,-1.0,-1.0,-1
"""METHODS: This prospective, open-label phase II trial recruited patients aged â‰¥ 75 years with previously untreated mCRC between March 2010 and January 2012""",0.0,0.0,0.0,0
"""Ten out of 12 (83.3%) RAS wild-type PDTOs responded to cetuximab, while all the mutant PDTOs, 8 out of 8 (100%), were resistant""",-1.0,-1.0,-1.0,-1
"""The objective of the current study was to evaluate the addition of bevacizumab (BEV) to preoperative capecitabine (CAP)-based CRT in LARC, and to explore biomarkers for downstaging""",-1.0,-1.0,-1.0,-1
The addition of utidelone was not cost-effective when it was $115.4 per 30â€‰mg-the price of its analog paclitaxel,-1.0,-1.0,-1.0,-1
"""The 5-year overall survival rates were 52Â·1% (95% CI 46Â·3-57Â·5) for the adjuvant-CapOx group, 61Â·0% (55Â·3-66Â·2) for the adjuvant-SOX group, and 60Â·0% (54Â·2-65Â·3), for the perioperative-SOX group""",-1.0,-1.0,-1.0,-1
OBJECTIVE: This study aimed at assessing the efficacy and safety of oxaliplatin plus oral capecitabine (XELOX regimen) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC),-1.0,-1.0,-1.0,-1
"""In terms of long-term efficacy, the XEC-XT treatment was superior to the FEC-T and TEC treatment, and there was no significant difference between the FEC-T and TEC groups.""",-1.0,-1.0,-1.0,-1
"""However, several clinical studies that tested S-1 plus oxaliplatin (SOX) indicate that SOX is also a treatment option for mCRC""",-1.0,-1.0,-1.0,-1
Advanced age alone should not be the only criteria to preclude effective therapy in elderly patients with CRC,0.0,0.0,0.0,0
"""Therefore, patients were orally administered oxycodone hydrochloride hydrate (OxinormÂ®) 45Â min prior to oxaliplatin administration""",-1.0,-1.0,0.0,0
This dose-toxicity model will be useful in developing Bayesian individual treatment adaptations and may be of use in the clinic.,0.0,-1.0,1.0,1
In this year's American Society of Clinical Oncology (ASCO) Annual Meeting four remarkable studies were presented regarding this vulnerable group of patients,0.0,0.0,0.0,0
The primary endpoint was the fraction of patients not fulfilling the criteria for adjuvant chemotherapy (converted patients),0.0,0.0,0.0,0
PURPOSE: The purpose of this study was to evaluate the adverse drug reactions (ADRs) and serious adverse events associated with capecitabine use in Korean patients by analyzing data from a comprehensive national database of adverse events,1.0,1.0,1.0,1
DESIGN: We developed a Markov model to compare the healthcare and economic outcomes of FLOT and ECF/ECX in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma,-1.0,-1.0,-1.0,-1
"""CONCLUSION: Due to the small sample size following early termination, no definitive conclusions can be drawn in relation to the noninferiority of CAPIRI compared with FOLFIRI.""",-1.0,-1.0,-1.0,-1
"""RESULTS: Between October 2007 and November 2008, a total of 42 patients were enrolled in the study (median age 51 years",0.0,0.0,0.0,0
METHODS: This non-crossover phase III double-blinded clinical trial randomized patients in a 1:1 ratio to either a control group or to a group administered a structured teaching model including intensive prophylactic measures on HFS administered by a trained oncology nurse at regular intervals (case) versus standard information on HFS care administered by treating clinician (control),0.0,0.0,0.0,0
"""Addition of the targeted agents trastuzumab, bevacizumab, and lapatinib to chemotherapy has produced significant benefits in time to progression and progression-free survival""",-1.0,-1.0,-1.0,-1
"""CONCLUSION: The incidence of cardiotoxicity associated with raltitrexed in patients with advanced CRC treated is favourable in a highly skewed, at-risk patient population, all of whom had documented cardiotoxicity with other fluoropyrimidines or were unable to tolerate capecitabine due to cardiac history""",-1.0,-1.0,1.0,1
"""METHODS: During this pilot, randomized, triple-blinded, placebo-controlled clinical trial, the effect of AlphaÂ® ointment (Lawsonia inermis 3Â g and Curcuma longa 0.15Â g/ 30Â g) was assessed""",0.0,-1.0,-1.0,0
"""DLT was defined as toxicity leading to postponement of treatment, a drug dose reduction or definitive interruption of drug administration""",1.0,0.0,1.0,1
"""Objective response occurred in 43 (55.1%) of the patients (complete 6.4% and partial response 48.7%",0.0,0.0,0.0,0
"""RESULTS: A total of 52 patients were enrolled, 30 of whom received wXELIRI as first-line treatment and 22 as second-line treatment""",-1.0,-1.0,-1.0,-1
"""Based on this background, we evaluated the outcome of patients with HER2-negative metastatic gastric cancer (mGC) who received in the clinical practice a triplet or doublet regimen as first-line therapy""",-1.0,-1.0,-1.0,-1
"""One level-III patient developed grade 4 neutropenia, while another developed grade 3 radiation esophagitis""",1.0,1.0,1.0,1
We aimed to investigate the differences in efficacy and safety between bevacizumab combined with capecitabine maintenance therapy and capecitabine monotherapy for RAS-mutant mCRC ï¼ˆas defined by mutations in KRAS and NRAS exons 2-4ï¼‰controlled by bevacizumab plus FOLFIRI chemotherapy for at least 12Â weeks,0.0,-1.0,1.0,1
Tumor response was assessed by the response evaluation criteria in solid tumors (RECIST criteria) and survival was calculated from initiation of CapGem therapy,-1.0,0.0,0.0,-1
A high rate of capecitabine treatment modification was required with capecitabine 1050 mg/m(2) bid (dose level 3),0.0,0.0,1.0,0
"""Developed multivariable models had AUCs (area under curve) ranging from 0.625 to 0.888 and 0.428 to 0.760 in the training and validation set, respectively""",0.0,-1.0,0.0,0
"""The incidence of severe HFS was significantly lower in patients who received PPIs (18%) than in patients who did not receive PPIs (43%, p=0.001), and the discontinuation rate of capecitabine therapy due to HFS was also lower in patients receiving PPIs than in those who did not receive PPIs (p=0.003)""",1.0,1.0,0.0,1
"""To enhance the survival of patients with metastatic colorectal cancer, many therapies are administered""",0.0,0.0,0.0,0
"""Secondary objectives are safety and tolerability, efficacy in terms of progression-free survival and objective response rate and blood-based signatures (e.g""",1.0,1.0,1.0,1
"""Patients with KRAS, BRAF or PIK3CA mutation or unknown mutational status received three cycles of capecitabine 2000 mg/m(2) days 1-14 q3w and oxaliplatin 130 mg iv day 1 q3w""",-1.0,-1.0,0.0,-1
"""PATIENTS AND METHODS: Women with MBC were randomly assigned to receive either capecitabine (Cap arm: 1250 mg/m(2) twice daily, on days 1-14) or vinorelbine/gemcitabine doublet (VG arm: vinorelbine 25 mg/m(2)",-1.0,-1.0,0.0,0
"""Twelve percent of patients received chemotherapy with radioembolization (nÂ = 72), and 88% of patients (nÂ = 513) received only chemotherapy""",0.0,0.0,0.0,0
Plasma folate and folic acid levels were determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) and were available for 212 patients,-1.0,0.0,0.0,0
"""Mid-treatment, low preference was associated with lower QoL, worse social, emotional and physical function (all pâ€¯â‰¤â€¯0.02) and worse nausea/vomiting, cancer symptoms and financial worries (all pâ€¯<â€¯0.05)""",1.0,0.0,1.0,1
"""RESULTS: DPYD variant allele carriers treated with standard dosages (NÂ =Â 34) showed an increased risk of severe gastrointestinal (adjusted ORÂ =Â 2.58, confidence interval [CI]Â =Â 1.02-6.53, PÂ =Â 0.045) or severe haematological (adjusted ORÂ =Â 4.19, CIÂ =Â 1.32-13.25, PÂ =Â 0.015) toxicity compared with wild-type patients (NÂ =Â 771)""",1.0,1.0,1.0,1
"""Deficiencies in DPD activity have been shown to cause 5FU-treated cancer patients to experience severe drug-related toxicities, often requiring extensive medical intervention""",1.0,1.0,1.0,1
"""CASE PRESENTATION: The patient is a 65-year-old male with node negative, high-grade adenocarcinoma of the rectum penetrating through the distal rectal wall""",0.0,0.0,0.0,0
"""CONCLUSIONS: The combination of capecitabine, oxaliplatin and bevacizumab is an effective and safe combination for the treatment of elderly patients with metastatic CRC""",-1.0,-1.0,-1.0,-1
"""PATIENTS AND METHODS: Treatment-naive eligible patients (n = 69) received intravenous gemcitabine (1,000 mg/m(2)) and oxaliplatin (100 mg/m(2)) every 2 weeks for four doses, followed by radiation (50.4 Gy to the gross tumor only) with concurrent capecitabine (825 mg/m(2) twice daily on radiation treatment days)""",-1.0,-1.0,0.0,0
"Treatment-naive eligible patients (n = 69) received radiation (50.4 Gy to the gross tumor only) with concurrent capecitabine (825 mg/m(2) twice daily on radiation treatment days)""",,,,0
"""Patients can be categorised in normal, moderate and poor DPYD metabolisers to predict the risk of adverse events of capecitabine treatment""",1.0,1.0,1.0,1
"""Capecitabine has been shown to be much less cardiotoxic compared to 5-FU, with only a handful of cases reporting cardiotoxicity with capecitabine""",1.0,1.0,1.0,1
"""CONCLUSION: Adding PA-MSHA to capecitabine has a good safety profile in patients with heavily pre-treated MBC, although benefit from this regimen might occur only in patients with moderate PA-MSHA-related adverse events""",1.0,-1.0,-1.0,-1
CONCLUSION: capecitabine has a good safety profile with moderate related adverse events,,,,1
